JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Igarashi, K.
Right arrow Articles by Williams, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Igarashi, K.
Right arrow Articles by Williams, K.

Vol. 283, Issue 2, 533-540, 1997

Benzyl-polyamines: Novel, Potent N-Methyl-D-aspartate Receptor Antagonists1

Kazuei Igarashi2 , Akira Shirahata, Albert J. Pahk, Keiko Kashiwagi2 and Keith Williams

Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania (K.I., A.J.P., K.K., K.W.), Faculty of Pharmaceutical Sciences, Chiba University, Inage-ku, Chiba 263, Japan (K.I., K.K.), and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado, Saitama 350-02, Japan (A.S.)


    Abstract
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The effects of benzyl-polyamines were studied at recombinant N-methyl-D-aspartate (NMDA) receptors expressed in Xenopus laevis oocytes. A number of mono-, di- and tri-benzyl polyamines, having benzyl substitutions on the terminal or central amino groups, inhibited responses of NR1/NR2 receptors in oocytes voltage-clamped at -70 mV. Among the most potent compounds was N1,N4,N8-tri-benzyl-spermidine (TB-3-4), which had an IC50 value of 0.2 µM. TB-3-4 was ~40-fold more potent at NR1/NR2A and NR1/NR2B receptors than at NR1/NR2C or NR1/NR2D receptors. Block by TB-3-4 was strongly voltage dependent. Using voltage ramps analyzed by the Woodhull model of voltage-dependent channel block, TB-3-4 was found to have a Kd(0) value of 5 µM and a zdelta value of 1.41 at NR1/NR2B channels, whereas the affinity of binding [Kd(0) = 250 µM] but not the degree of voltage-dependence (zdelta  = 1.43) was much lower at NR1/NR2D channels. At a concentration of 10 µM, TB-3-4 had no effect on alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors expressed from the GluR1 subunit, indicating that TB-3-4 is a selective NMDA antagonist. TB-3-4 did not permeate wild-type NMDA channels but could easily permeate channels containing an N616G mutation in the NR1 subunit. This mutation is presumed to increase the size of the narrowest constriction of the NMDA channel, thus allowing passage of TB-3-4. Benzyl-polyamines such as TB-3-4 represent a structurally novel class of NMDA receptor channel blockers.


    Introduction
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

NMDA receptors are involved in excitatory synaptic transmission and synaptic plasticity. Overactivation of these receptors can lead to neuronal cell death, and the receptors also play a role in seizure activity. Thus, NMDA receptors are potential targets for neuroprotective agents and anticonvulsants (Choi, 1988; Rogawski, 1992). NMDA receptors have a complex pharmacology and are targets for antagonists acting at the glutamate and glycine coagonist sites, at a large number of modulatory sites and at sites within the ion channel of the receptor (McBain and Mayer, 1994). The cDNAs encoding a number of subunits of NMDA receptors have been cloned, including the NR1 and NR2A, NR2B, NR2C and NR2D subunits (Hollmann and Heinemann, 1994; Moriyoshi et al., 1991). Native NMDA receptors are probably hetero-oligomers containing combinations of NR1 and NR2 subunits (Luo et al., 1997; Sheng et al., 1994). Recombinant NMDA receptors expressed from particular combinations of cloned subunits are a valuable experimental system with which to study the structure and function of the receptors and the site and mechanism of action of receptor antagonists.

A number of organic polycations, including the endogenous polyamines spermine and spermidine, are antagonists at native and recombinant NMDA receptors (Williams, 1997). When applied extracellularly, polyamines act as open-channel blockers at NMDA receptors and may also reduce currents through these channels by screening of surface charges (Araneda et al., 1993; Benveniste and Mayer, 1993; Rock and Macdonald, 1992). Spermine and spermidine are, however, very weak blockers of NMDA channels, being active at high micromolar to millimolar concentrations. Polyamine-conjugated spider and wasp toxins, containing an aromatic head group and polyamine tail, have been found to be potent glutamate receptor antagonists (Jackson and Usherwood, 1988). These toxins block invertebrate glutamate receptors, and in some cases, they also block mammalian NMDA and AMPA/kainate receptors. Such compounds are useful as tools to study the structure and function of glutamate receptors, although many of the toxins are unstable and are difficult to obtain because their syntheses are complex. We have recently found that N1-dansyl derivatives of spermine and spermidine are potent NMDA channel blockers, being several hundred- to several thousand-fold more potent than the native polyamines (Chao et al., 1997). N1-Dansyl-polyamines contain a hydrophobic substitution at one terminal amino group, but the remainder of the polyamine chain is intact. Because of the potent activities of dansyl-polyamines, we examined other polyamine derivatives with hydrophobic substitutions. Here, we describe the effects of benzyl-substituted polyamines. A number of di- and tri-benzyl polyamines were found to be potent NMDA receptor antagonists. Surprisingly, the most potent compounds were N,N',N''-tri-benzyl triamines, such as the spermidine derivative TB-3-4, with a benzyl substitution on each of the three amino groups. Tri-benzyl-polyamines represent a new class of NMDA receptor antagonists that may be useful as tools to study NMDA channels and as lead compounds for novel neuroprotective or anticonvulsant agents.

    Materials and Methods
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

cDNA clones. The NR1 clone (Moriyoshi et al., 1991) and the NR1(N616Q) mutant were gifts from Dr. S. Nakanishi (Institute for Immunology, Kyoto University Faculty of Medicine, Kyoto, Japan). The NR1(N616R) mutant was a gift from Dr. R. J. Dingledine (Department of Pharmacology, Emory University, Atlanta, GA). The splice variant of NR1 used in these studies was NR1A (Moriyoshi et al., 1991; Sugihara et al., 1992). The NR2A and NR2B clones (Monyer et al., 1992) were gifts from Dr. P. H. Seeburg (Center for Molecular Biology, University of Heidelberg, Germany). The mouse NR2C and NR2D clones (epsilon 3 and epsilon 4) (Ikeda et al., 1992; Kutsuwada et al., 1992) were gifts from Dr. M. Mishina (Department of Pharmacology, University of Tokyo, Japan). The NR1(N616G) mutant was prepared as described previously (Chao et al., 1997), and amino acids are numbered from the initiator methionine in NR1 and NR2 clones (Ishii et al., 1993; Moriyoshi et al., 1991). The GluR1 clone (Hollmann et al., 1989) was a gift from Drs. J. Boulter and S. F. Heinemann (The Salk Institute for Biological Studies, La Jolla, CA).

Preparation of oocytes and voltage-clamp recording. The preparation and maintenance of oocytes were carried out as described previously (Williams et al., 1993). Capped cRNAs were prepared from linearized cDNA templates using mMessage mMachine kits (Ambion, Austin, TX). NR1 and NR2 subunits were injected in a ratio of 1:5 (0.25-4 ng of NR1 + 1.25-20 ng of NR2). Macroscopic currents were recorded with a two-electrode voltage-clamp using an OC-725 amplifier (Warner Instruments, Hamden, CT) or a GeneClamp 500 amplifier (Axon Instruments, Foster City, CA). Oocytes were continuously superfused (~5 ml/min) with a Mg++-free saline solution (96 mM NaCl, 2 mM KCl, 1.8 mM BaCl2, 10 mM HEPES, pH 7.5), which contained BaCl2 rather than CaCl2 to minimize Ca++-activated Cl- currents (Leonard and Kelso, 1990). In most experiments with NMDA receptors, oocytes were injected with K+-BAPTA (100 nl; 40 mM, pH 7.0) on the day of recording (Williams, 1993).

To obtain values for the IC50 and Hill slope (nH) of antagonists, data from concentration-inhibition curves were fit to equation 1:
I<IT>=100/1+</IT>([antagonist]<IT>/</IT>IC<SUB><IT>50</IT></SUB>)<SUP><IT>n</IT><SUB><IT>H</IT></SUB></SUP> (1)
where I is the response to glutamate measured in the presence of antagonist and expressed as a percentage of the control response to glutamate. Voltage-dependence of block by polyamines was analyzed using the Woodhull model of voltage-dependent channel block (Woodhull, 1973) by fitting data from voltage ramps to equation 2:
I<SUB>glu+PA</SUB>/I<SUB>glu</SUB><IT>=&agr;/</IT>[<IT>1+</IT>{[PA]<IT>/K</IT><SUB><IT>d</IT></SUB>(<IT>0</IT>)exp(z&dgr;FV/RT)}] (2)
where Iglu is the current induced by glutamate, Iglu + PA is the current induced by glutamate in the presence of the polyamine, alpha  is the fraction of the block that is voltage dependent, Kd(0) is the equilibrium dissociation constant of the polyamine at a transmembrane potential of 0 mV, z is the charge of the polyamine, delta  is the fraction of the membrane electric field sensed by the blocker at its binding site within that field, F is the Faraday constant, R is the gas constant and T is the absolute temperature. The alpha  function was included in equation 2 because in some cells the glutamate response showed a small run-down or run-up over time, and the fractional recovery from block at depolarized potentials was slightly different from 1.0; the inclusion of the alpha  variable improves the fitting procedure (Chao et al., 1997).

Synthesis of benzyl-polyamines. Benzyl-polyamines were prepared as the hydrochloride forms. The mono- and tri-benzyl derivatives 4-MB-3-3, 5-MB-4-4, TB-3-3, TB-3-4 and TB-4-4 (Niitsu and Samejima, 1986) and 4,9-DB-3-4-3 (Samejima et al., 1984) were synthesized as described previously.3 The other di-benzyl derivatives, DB-3, DB-7, DB-10, DB-3-3, DB-3-4, DB-4-4 and 1,12-DB-3-4-3, were synthesized using a method previously described for the synthesis of di-benzyl-putrescine but using an appropriate diamine (e.g., diaminoheptane for DB-7) or triamine (e.g., spermidine for DB-3-4) for synthesis of the corresponding di-benzyl-polyamine (Samejima et al., 1984).

    Results
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Activities of benzyl-polyamines. A number of mono-, di- and tri-benzyl polyamines were studied. The effects of these compounds on responses to glutamate (10 µM; with 10 µM glycine) were measured at NR1/NR2A receptors in oocytes voltage-clamped at -70 mV (fig. 1). We initially studied mono- and di-benzyl polyamine derivatives. At concentrations of 1 to 10 µM, the di-benzyl-diamines DB-3, DB-7 and DB-10 inhibited responses to glutamate and were slightly more potent than di-benzyl-triamines (DB-3-3 and DB-3-4) of a similar chain length (fig. 1). The mono-benzyl triamines 4-MB-3-3 and 5-MB-4-4, which have a benzyl group attached to the central nitrogen, had activities similar to the terminal di-benzyl diamines (DB-7, DB-10) and triamines (DB-3-3 and DB-4-4) of equivalent chain length, suggesting that benzylation at either the terminal or central amino groups increases the potency of polyamines as NMDA antagonists. This conclusion was supported by the finding that the tri-benzyl triamines TB-3-3, TB-3-4 and TB-4-4 were more potent than their mono-benzyl analogs (4-MB-3-3 and 5-MB-4-4) or their di-benzyl analogs (DB-3-3, DB-3-4 and DB-4-4). Two spermine derivatives, 1,12-DB-3-4-3 and 4,9-DB-3-4-3, were also potent antagonists, with 4,9-DB-3-4-3 having activity similar to the spermidine derivative TB-3-4 (fig. 1).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of polyamine analogs at NMDA receptors. The effects of spermidine, spermine and mono-, di- and tri-benzyl polyamines, each at 1 and 10 µM, on responses to glutamate (10 µM; with 10 µM glycine) were determined in oocytes expressing NR1/NR2A receptors and voltage-clamped at -70 mV. Data are expressed as a percentage of the control response to glutamate. Values are mean ± S.E.M. from four to seven oocytes for each compound. The structures of the analogs are also shown.

The tri-benzyl derivative TB-3-4 was one of the most potent benzyl-polyamine antagonists, and this derivative is most closely related to the endogenous triamine spermidine. The effects of TB-3-4 were characterized in detail. To determine the subunit selectivity of block by TB-3-4 at NMDA receptors, we measured concentration-inhibition curves at NR1/NR2 receptors containing the NR2A, NR2B, NR2C and NR2D subunits (fig. 2). TB-3-4 was 20- to 50-fold more potent at NR1/NR2A and NR1/NR2B receptors than at NR1/NR2C and NR1/NR2D receptors (fig. 2; table 1).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 2.   Subunit-specific block of NMDA receptors. A, The effects of various concentrations of TB-3-4 on responses to glutamate (glu, 10 µM; with 10 µM glycine) were determined in an oocyte expressing NR1/NR2A receptors and voltage-clamped at -70 mV. For illustration, traces have been normalized to the glutamate response at the beginning of the test pulse for each concentration of TB-3-4 because the response to glutamate showed a small (12%) rundown over the course of the experiment. Thus, calibration bars are shown next to the first and last traces. B, Concentration-inhibition curves for TB-3-4 were determined at NR1/NR2 receptors containing NR2A, NR2B, NR2C and NR2D subunits using protocols similar to those shown in A. Values are mean ± S.E.M. from four to seven oocytes for each subunit combination.


                              
View this table:
[in this window]
[in a new window]
 
TABLE 1
Effects of TB-3-4 at wild-type and mutant NMDA receptors

The effects of TB-3-4 were measured at NR1/NR2 receptors containing wild-type and mutant NR1 subunits in oocytes voltage-clamped at -70 mV. Values for the IC50, mean (-S.E.M., +S.E.M.), and Hill slope (nH; mean ± S.E.M.) were determined from concentration-inhibition curves with five or six concentrations of TB-3-4 at each receptor type.

To determine whether the benzyl polyamines were selective NMDA receptor antagonists, we studied the effects of TB-3-4 and 4,9-D-B-3-4-3 at NMDA receptors and at AMPA receptors expressed from the GluR1 subunit (fig. 3). In these experiments, we also determined the effects of N1-DnsSpm (Chao et al., 1997), a polyamine analog with a potency (IC50 = 0.3 µM at -70 mV) similar to that of TB-3-4 at NR1/NR2A receptors. In oocytes voltage-clamped at -70 mV, TB-3-4 and 4,9-DB-3-4-3 (10 µM) produced an almost complete block of NR1/NR2A receptors but had little or no effect on responses to kainate at GluR1 receptors (fig. 3). In contrast, N1-DnsSpm (1 µM) was a potent antagonist at both NMDA and GluR1 receptors (fig. 3), and recovery from block by N1-DnsSpm at GluR1 channels was very slow. Thus, although TB-3-4 and 4,9-DB-3-4-3 have potencies similar to N1-DnsSpm at NMDA receptors, the compounds have a markedly different profile at GluR1 receptors.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of polyamine analogs at NMDA and AMPA receptors. A and B, Effects of TB-3-4, 4,9-DB-3-4-3 and N1-DnsSpm were determined at NR1/NR2A receptors (A) activated by glutamate (glu, 10 µM; with 10 µM glycine) and at GluR1 receptors (B) activated by 100 µM kainate (KA) in oocytes voltage-clamped at -70 mV. All horizontal scale bars in A and B are 30 sec. Recovery from block by 10 µM 4,9-DB-3-4-3 at NR1/NR2A receptors and by N1-DnsSpm at GluR1 receptors was extremely slow and sometimes incomplete. The breaks in the traces correspond to 13 min (NR1/NR2A) and 8 min (GluR1). C, Responses to glutamate or kainate measured in the presence of polyamines are expressed as a percentage of the control response at each receptor type. Values are mean ± S.E.M. from four to seven oocytes.

Voltage-dependence and permeation through NMDA channels. TB-3-4 did not act as a competitive antagonist at the glutamate or glycine sites because inhibition by TB-3-4 (0.3 µM) was not overcome by increasing the concentrations of glutamate and glycine over the range of 0.3 to 10 µM (data not shown). Benzyl-polyamines including TB-3-4 may act as NMDA channel blockers, similar to spermine itself and to polyamine analogs such as N1-DnsSpm. Consistent with this idea, the block by TB-3-4 was strongly voltage dependent, being more pronounced at hyperpolarized membrane potentials (fig. 4).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 4.   Voltage-dependent block by TB-3-4. A, I-V curves were constructed by voltage ramps (-150 to +30 mV over 6 sec; inset) at NR1/NR2B and NR1/NR2D receptors activated by glutamate (10 µM; with 10 µM glycine) in the absence and presence of 1 µM TB-3-4. Leak currents have been subtracted. B, Currents measured in the presence of TB-3-4 (Iglu+TB-3-4) are expressed as a fraction of the control current (Iglu) for each oocyte. The solid lines are fits to the Woodhull model (text equation 2), which was fit from +30 to -100 mV (NR1/NR2B) and from +30 to -115 mV (NR1/NR2D) and extrapolated to -150 mV. Data around the reversal potential were masked during the fitting procedure.

To characterize the block by TB-3-4, I-V curves were constructed by voltage-ramps and analyzed using the Woodhull model of voltage-dependent channel block (Woodhull, 1973) (fig. 4). In this model, the charged polyamine is assumed to bind to a site within the membrane-spanning portion of the ion channel and the affinity of binding is exponentially related to the transmembrane potential. The model was used to determine values for Kd(0), and for the apparent valence, zdelta , where z is the charge of the polyamine and delta  is the depth of the binding site within the membrane electric field. Because the potency of TB-3-4 is 30- to 50-fold greater at receptors containing NR2A or NR2B than at receptors containing NR2C or NR2D (fig. 2), we studied block at NR1/NR2A, NR1/NR2B and NR1/NR2D channels to determine whether the difference in potency is due to a difference in the voltage-dependence or the affinity of binding of TB-3-4 at NR1/NR2D compared with NR1/NR2A and NR1/NR2B channels (fig. 4). Block by TB-3-4 was steeply voltage dependent, with zdelta values of 1.44 ± 0.02 at NR1/NR2A channels (n = 5), 1.41 ± 0.02 at NR1/NR2B channels (n = 5) and 1.43 ± 0.02 at NR1/NR2D channels (n = 3). The value of Kd(0) was 40- to 50-fold greater at NR1/NR2D than at NR1/NR2A or NR1/NR2B channels. Values of Kd(0), geometric mean (-S.E.M., +S.E.M.), were 5.1 µM (4.8, 5.4 µM) at NR1/NR2A, 5.6 µM (4.8, 6.6 µM) at NR1/NR2B and 250 µM (188, 330 µM) at NR1/NR2D channels. Thus, the difference in the potency of TB-3-4 at NR1/NR2D receptors compared with NR1/NR2A or NR1/NR2B is due entirely to a difference in the affinity of binding of TB-3-4 [i.e., Kd(0)] with no change in voltage-dependence (fig. 4).

The value of zdelta for block by TB-3-4 was 1.41 at NR1/NR2B channels. Assuming that all three amino groups of TB-3-4 are fully protonated at physiological pH (i.e., z = +3), the average fraction of the membrane electrical field sensed by TB-3-4 at its binding site within the channel (i.e., delta ) is 0.47. We also studied block by the benzylated tetra-amine 4,9-DB-3-4-3 (0.1 µM) at NR1/NR2B channels using voltage ramps analyzed by the Woodhull model. The value of Kd(0) was 16 ± 3 µM, and the value of zdelta was 1.60 ± 0.02 (n = 5) for 4,9-DB-3-4-3. Assuming that z = +4 for 4,9-DB-3-4-3, then the value of delta  for the 4,9-DB-3-4-3 binding site is 0.40, similar to that for TB-3-4.

Many NMDA channel blockers show a use-dependent form of antagonism, binding to and blocking the open state but not the closed state of the NMDA channel. In studies involving measurements of macroscopic currents on oocytes, it is sometimes possible to determine whether block by an antagonist is use-dependent by comparing the block that is produced when the antagonist is applied in the absence and presence of agonist (i.e., to closed and open channels). The experimental paradigms for such studies require that the onset and/or recovery from block are relatively slow compared with the solution exchange time of the bath. The onset of block by TB-3-4 is too rapid to use these paradigms, but the relatively slow recovery from block seen with high concentrations of TB-3-4 (e.g., figs. 2A and 3A) suggests that one could measure use-dependence by studying recovery from block. However, in control experiments, we found that the slow recovery from block seen with high concentrations of TB-3-4 is due to slow washout of the compound from the bath and/or perfusion system rather than slow dissociation from NMDA channels (data not shown). Thus, using two-electrode voltage-clamp recording and bath application of benzyl-polyamines, we have not been able to determine whether the effects of these compounds are use-dependent.

An asparagine residue (N616) in the pore-forming region of the NR1 subunit has been shown to influence sensitivity to block by extracellular Mg++ (Burnashev et al., 1992; Kawajiri and Dingledine, 1993; Mori et al., 1992; Sakurada et al., 1993), spermine (Kashiwagi et al., 1997) and N1-DnsSpm (Chao et al., 1997). This residue appears to lie directly in the cation permeation pathway and may contribute to the narrowest constriction of the NMDA channel (Wollmuth et al., 1996). Mutations at N616 can decrease or increase the potency of polyamine channel blockers, depending on the amino acid substituted at position 616 (Chao et al., 1997), and mutations (such as N-to-G) that decrease the size of the side-chain at position 616 can increase the permeability for organic cations such as tetraethylammonium, presumably by increasing the size of the narrow constriction in the pore (Wollmuth et al., 1996). Mutation N616G was also found to dramatically increase permeation of N1-DnsSpm through NMDA channels, presumably by increasing pore size and allowing passage of the bulky naphthalene head group of N1-DnsSpm (Chao et al., 1997). Experiments were carried out to determine whether residue N616 in NR1 influences block by TB-3-4 and whether TB-3-4 can permeate NMDA channels.

Mutations were studied that changed the asparagine at position 616 to glycine (N616G), glutamine (N616Q) and arginine (N616R) (table 1). In oocytes voltage-clamped at -70 mV, the NR1(N616Q) and NR1(N616G) mutations had only modest effects on sensitivity to TB-3-4, reducing the potency of TB-3-4 by 2- to 4-fold when the mutants were coexpressed with NR2A or NR2B. In contrast, the NR1(N616R) mutation reduced the potency of TB-3-4 by ~600-fold (table 1).

Residue NR1(N616) affects permeation of cations and channel blockers; therefore, the effects of mutations at NR1(N616) on permeation of TB-3-4 were studied. The approach that was used for these experiments was to study the reversal of block by TB-3-4 at extreme hyperpolarized membrane potentials. Using this approach, we have previously shown that block of NMDA receptors by some long-chain polyamine analogs, such as the penta-amine BE4444, is complete at a membrane potential of ~-100 mV but is relieved at more negative (-100 to -200 mV) as well as at more positive membrane potentials (Igarashi and Williams, 1995). Block by N1-DnsSpm is complete, and no recovery is seen at membrane potentials of -100 to -200 mV at wild-type NR1/NR2A receptors, whereas relief of block is seen over the same voltage range at NR1(N616G)/NR2A receptors. The relief of block at extreme negative membrane potentials reflects permeation of BE4444 through wild-type NR1/NR2 channels and permeation of N1-DnsSpm through NR1(N616G)/NR2A channels (Chao et al., 1997; Igarashi and Williams, 1995).

The results of experiments designed to study permeation of TB-3-4 are shown in figure 5. In these experiments, I-V curves were constructed by using linear voltage ramps from -185 mV to +40 mV in the absence and presence of 0.3 µM TB-3-4 (fig. 5A) and 3 µM TB-3-4. To assess the degree of recovery at very negative membrane potentials (an index of the degree of permeation of TB-3-4), we compared the fractional block at -100 and -170 mV (fig. 5B). If the degree of block simply increases at more negative membrane potentials and there is no relief from block, the value shown in figure 5B will be smaller at -170 mV than at -100 mV (i.e., the fractional block is larger at -170 than at -100 mV). If there is no increase in block or some relief from block at extreme negative potentials, the value at -170 mV will be equal to or larger than at -100 mV (i.e., the fractional block is smaller at -170 than at -100 mV). Block by 0.3 µM TB-3-4 showed little or no recovery at extreme negative membrane potentials at wild-type NR1/NR2A receptors, whereas there was modest recovery at NR1(N616Q)/NR2A receptors and very pronounced recovery at NR1(N616G)/NR2A receptors (fig. 5). Block by a 10-fold higher concentration of TB-3-4 (3 µM) was almost complete at NR1/NR2A and NR1(N616Q)/NR2A receptors at -100 and -170 mV, and there was only minimal recovery from block at -170 mV with the N616Q mutant, but there was still a dramatic recovery from block at the N616G mutant under these conditions (fig. 5B). These data suggest that TB-3-4 can only weakly permeate wild-type NR1/NR2A channels but that there is a modest increase in permeation of TB-3-4 with the NR1(N616Q) mutant and a large increase in permeation with the NR1(N616G) mutant.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   Permeation of TB-3-4 through mutant NMDA channels. A, I-V curves were constructed by voltage-ramps from -185 to +40 mV (see inset in NR1/NR2A) at cells expressing NR1/NR2A, NR1(N616Q)/NR2A and NR1(N616G)/NR2A receptors. Responses to 10 µM glutamate (with 10 µM glycine) were measured in the absence (control) and presence of 0.3 µM TB-3-4. Leak currents have been subtracted. B, Glutamate currents measured in the presence of 0.3 µM or 3 µM TB-3-4 (Iglu + TB-3-4) are expressed as a fraction of the control glutamate current (Iglu) at -100 and -170 mV. Data were obtained from voltage ramps similar to those shown in A and are mean ± S.E.M. from five to nine oocytes for each subunit combination.

    Discussion
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

In this study, we found that N-benzyl polyamines are potent NMDA receptor antagonists. The rationale for studying benzyl-polyamines was based on the finding that linear polyamines with a hydrophobic substitution at one end of the polyamine chain, such as the polyamine-conjugated spider toxins or the spermine derivative N1-DnsSpm, are potent NMDA channel blockers. In these molecules, the linear polyamine chain remains intact, and we have proposed that the polyamine tail of N1-DnsSpm may enter deep into the ion channel pore with the head group of the molecule interacting with more peripheral residues in the mouth of the channel (Chao et al., 1997; Kashiwagi et al., 1997). Furthermore, bis(ethyl)penta-amines, which have hydrophobic substitutions on the terminal amino groups, are potent NMDA channel blockers (Igarashi and Williams, 1995). We hypothesized that benzyl substitutions at the terminal amino groups of polyamines may increase their potencies as NMDA channel blockers. We also wanted to determine the effects of benzyl-substitutions at the central imino groups of polyamines because hydrophobic substitutions at these positions have not been studied previously. The N-benzyl substitutions increased the potencies of polyamines, and the most potent benzyl derivatives were N4,N9-di-benzyl-spermine (4,9-DB-3-4-3), in which the benzyl groups are attached to the central imino groups, and tri-benzyl-triamines such as N1,N4,N8-tri-benzyl-spermidine (TB-3-4), which has benzyl substitutions at the terminal amino and central imino groups.

Many of the polyamine-conjugated spider toxins block AMPA or kainate receptors in addition to NMDA receptors, and none of the known toxins are highly selective for NMDA channels. Similarly, N1-DnsSpm is a potent voltage-dependent blocker of GluR1 AMPA channels4 as well as NMDA channels (Chao et al., 1997). Notably, TB-3-4, at a concentration 50-fold higher than its IC50 value at NR1/NR2A receptors, was almost inactive at GluR1 channels. Thus, the pharmacology of TB-3-4 is markedly different from that of N1-DnsSpm, with TB-3-4 being a selective NMDA antagonist. Compounds such as TB-3-4 and N1-DnsSpm are useful new tools to study the structural properties of glutamate receptor channels and to study differences in channel structure between different classes of receptors.

There are a number of possibilities that may account for the different profiles seen with simple N-substituted polyamines such as TB-3-4 and N1-DnsSpm. The potency of TB-3-4 (IC50 = 0.2 µM) is similar to that of N1-DnsSpm (IC50 = 0.3 µM) and is several thousand-fold greater than that of spermine or spermidine (IC50 = 500-1500 µM) (Chao et al., 1997). The increased potency of N1-DnsSpm compared with spermine is due in large part to an increase in voltage-dependence rather than to an increase in the affinity of binding, with the value of zdelta being 2.6 for N1-DnsSpm and 1.1 for spermine, and the Kd(0) value being 800 µM for N1-DnsSpm and 7400 µM for spermine (Chao et al., 1997). The Kd(0) value for TB-3-4 was 5 µM, suggesting that the affinity of the binding site for TB-3-4 is considerably higher than that for spermine or N1-DnsSpm and that the increase in the potency of TB-3-4 compared with spermine and spermidine is due largely to an increase in the affinity of binding with only a small increase in the voltage-dependence of block. Indeed, the value of zdelta for block by TB-3-4 (zdelta  = 1.41) is much less than that of N1-DnsSpm, and the calculated value of delta , the average depth of the membrane electric field sensed by the blocker, is much smaller for TB-3-4 (delta  = 0.47) than for N1-DnsSpm (delta  = 0.87). This suggests that the two polyamine analogs may bind to different sites within the channel pore of NMDA receptors. However, there are a number of limitations to these interpretations and to the use of the Woodhull model to characterize block of N-substituted polyamines. For example, it is not known whether only one molecule of the polyamine enters and binds to the channel or whether two or more molecules can simultaneously enter the channel. Similarly, it is not known whether all three of the charged amino groups of TB-3-4 and N1-DnsSpm enter the membrane electric field. If only one molecule of each polyamine enters the channel at a time, then TB-3-4 and N1-DnsSpm may have separate binding sites. However, if two molecules of N1-DnsSpm but only one of TB-3-4 can enter the channel, this may account for the observation that the value of zdelta for N1-DnsSpm is about twice that of the zdelta value for TB-3-4.

Some NMDA channel blockers can permeate the channel if the driving force for the blocker is made sufficiently large. Permeation of native or wild-type recombinant NMDA channels by low concentrations of Mg++, by spermine and by linear polyamine analogs such as BE4444 has been reported (Benveniste and Mayer, 1993; Igarashi and Williams, 1995; Mayer and Westbrook, 1987). Asparagine residues in NR1 and NR2 subunits, including N616 in NR1, control cation permeability and appear to form the narrowest constriction of the ion channel pore (Wollmuth et al., 1996). An asparagine-to-glycine (N-to-G) mutation at N616 increases the apparent size of this constriction from 0.55 to 0.75 nm. Paradoxically, an asparagine-to glutamine (N-to-Q) mutation (the side chain of Q is bulkier than of N) also produces a small increase in pore size, possibly because the bulky side chain of the Q residue does not pack well and disrupts channel structure (Wollmuth et al., 1996). N1-DnsSpm does not permeate wild-type NMDA channels or channels containing an NR1(N616Q) mutation but can easily permeate channels with the NR1(N616G) mutant (Chao et al., 1997). In this study, we found that TB-3-4 can apparently permeate some mutant NMDA channels at extreme negative membrane potentials.

Block by TB-3-4 showed little or no recovery at extreme negative potentials, suggesting that TB-3-4 does not easily permeate wild-type NMDA channels. Some recovery from block was seen at receptors containing the N-to-Q mutation and, in particular, at receptors containing the N-to-G mutation at NR1(N616). The diameter of the largest portion of TB-3-4 was estimated to be 0.6 to 0.65 nm, which is larger than the narrow constriction in wild-type channels (0.55 nm; Wollmuth et al., 1996; Zarei and Dani, 1995) but smaller than the diameter of the naphthalene ring of N1-DnsSpm (0.8-0.85 nm; Chao et al., 1997). This is consistent with the idea that TB-3-4 can permeate wild-type channels only poorly but can more easily permeate channels with the NR1(N616Q) or NR1(N616G) mutations. The smaller size of TB-3-4 compared with N1-DnsSpm could also account for the observation that TB-3-4 can permeate mutant channels more easily than N1-DnsSpm, an effect that is manifest as a more pronounced recovery from block at extreme negative potentials with TB-3-4 than with N1-DnsSpm (Chao et al., 1997). The effects of NR1(N616) mutations on block and permeation of TB-3-4 appear to be volume specific, influencing permeation of TB-3-4 with only modest effects on the potency of block. However, an N-to-R mutation, which introduces a positive charge at position N616, drastically reduced block by TB-3-4, and it is possible that NR1(N616) normally contributes to part of a binding site for TB-3-4 or that the introduction of a positive arginine residue at this position causes electrostatic repulsion of one or more of the amino groups in TB-3-4.

In conclusion, benzyl-polyamines such as TB-3-4 are a novel class of NMDA channel blocker that show selectivity for NMDA over AMPA channels. Benzyl-polyamines represent new tools to study GluR channels, and these compounds may bind to sites within the channel that are different from the binding sites for other polyamine derivatives, such as the dansyl-polyamines.

    Footnotes

Accepted for publication July 30, 1997.

Received for publication May 14, 1997.

1   This work was supported by United States Public Health Service Grant NS35047 from the National Institute of Neurological Disorders and Stroke, a Grant-in-Aid from the American Heart Association and a grant from the Japan Health Sciences Foundation.

2   Visiting scientists were supported by an International Scientific Research Program from the Ministry of Education, Science, Sports and Culture, Japan.

3   N,N'-Di-benzyl-diamines are referred to by the nomenclature DB-3, DB-7 and so forth, in which the number represents the number of methylene groups separating the amino groups. Thus, N1,N7-di-benzyl-diaminoheptane is DB-7. N,N'-Di-benzyl-triamines are referred to by the nomenclature DB-3-4, DB-4-4 and so forth, in which the numbers represent the number of methylene groups separating the amino and imino groups. Thus, N1,N8-di-benzyl-spermidine is DB-3-4. Similarly, N,N'-di-benzyl-tetra-amines are referred to by the nomenclature DB-3-4-3 and so forth, and N,N',N''-tri-benzyl-triamines are referred to by the nomenclature TB-3-4, TB-4-4 and so forth. Thus, N1,N4,N8-tri-benzyl-spermidine is TB-3-4.

4   This work and K. Williams, unpublished observations.

Send reprint requests to: Dr. Keith Williams, Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104-6084.

    Abbreviations

NMDA, N-methyl-D-aspartate; GluR, glutamate receptor; N1-DnsSpm, N1-dansyl-spermine; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; BAPTA, 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid; AMPA, alpha -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; I-V, current-voltage.

    References
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References


0022-3565/97/2832-0533$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1997 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
L. Jin, H. Sugiyama, M. Takigawa, D. Katagiri, H. Tomitori, K. Nishimura, N. Kaur, O. Phanstiel IV, M. Kitajima, H. Takayama, et al.
Comparative Studies of Anthraquinone- and Anthracene-Tetraamines as Blockers of N-Methyl-D-aspartate Receptors
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 47 - 55.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
G. Loussouarn, L. J. Marton, and C. G. Nichols
Molecular Basis of Inward Rectification: Structural Features of the Blocker Defined by Extended Polyamine Analogs
Mol. Pharmacol., August 1, 2005; 68(2): 298 - 304.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Kashiwagi, I. Tanaka, M. Tamura, H. Sugiyama, T. Okawara, M. Otsuka, T. N. Sabado, K. Williams, and K. Igarashi
Anthraquinone Polyamines: Novel Channel Blockers to Study N-Methyl-D-Aspartate Receptors
J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 884 - 893.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
K. Williams, M. Dattilo, T. N. Sabado, K. Kashiwagi, and K. Igarashi.
Pharmacology of delta 2 Glutamate Receptors: Effects of Pentamidine and Protons
J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 740 - 748.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
K. Kashiwagi, T. Masuko, C. D. Nguyen, T. Kuno, I. Tanaka, K. Igarashi, and K. Williams
Channel Blockers Acting at N-Methyl-D-aspartate Receptors: Differential Effects of Mutations in the Vestibule and Ion Channel Pore
Mol. Pharmacol., March 1, 2002; 61(3): 533 - 545.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
K.-K. Tai, S. E. Blondelle, J. M. Ostresh, R. A. Houghten, and M. Montal
An N-methyl-D-aspartate receptor channel blocker with neuroprotective activity
PNAS, March 13, 2001; 98(6): 3519 - 3524.
[Abstract] [Full Text] [PDF]


Home page
Pharmacol. Rev.Home page
R. Dingledine, K. Borges, D. Bowie, and S. F. Traynelis
The Glutamate Receptor Ion Channels
Pharmacol. Rev., March 1, 1999; 51(1): 7 - 62.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Igarashi, K.
Right arrow Articles by Williams, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Igarashi, K.
Right arrow Articles by Williams, K.


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition